What a Four-Year Vitamin D Trial Found About Aging

Participants taking 2,000 IU of vitamin D daily had significantly less telomere shortening over four years than the placebo group.* Researchers estimated the difference was roughly equivalent to preserving about three years of biological aging.*

Three years.

That got my attention.

Three years is a big claim. Big enough that I wanted to understand where that number came from.

So I looked at the study behind it.

Randomized. Placebo-controlled. Four years long.

Most vitamin D headlines over the years come from observational studies. They can show interesting patterns, but they cannot tell us whether vitamin D itself caused the outcome. This was different.

So I spent time digging into the paper.

Here is what the study actually did, what it found, and what it does not say.

WHAT THE STUDY ACTUALLY WAS

The VITAL Telomere sub-study was published in The American Journal of Clinical Nutrition in May 2025. It was co-led by researchers at Mass General Brigham and the Medical College of Georgia.

Researchers followed 1,054 adults, women over 55 and men over 50, pulled from the larger 26,000-person VITAL trial.

Participants took one of four options: vitamin D3, omega-3s, both, or a placebo. The vitamin D dose was simple: 2,000 IU daily.

Over four years, researchers measured telomere length in white blood cells at the beginning of the study, then again at year two and year four.

Quick refresher. Telomeres are protective caps at the ends of chromosomes. Every time cells divide, those caps gradually get shorter. Shorter telomeres have been linked with aging and age-related disease risk, which is why researchers pay attention to them.

No biomarker is perfect. Telomeres are not perfect either. But they are one of the more studied ways researchers try to understand cellular aging.

WHAT THEY FOUND

Researchers found significantly less telomere shortening in the vitamin D group. The estimated effect was roughly equivalent to preserving about three years of biological aging compared with placebo.*

A possible reason involves inflammation. Vitamin D appears to influence inflammatory pathways, and chronic inflammation has been linked with faster telomere shortening.*

Looking through the paper, three things jumped out at me.

First, this was a real randomized controlled trial.

A lot of vitamin D headlines over the years came from observational studies. Those studies can tell us that people with higher vitamin D levels often appear healthier. What they cannot tell us is whether vitamin D caused the difference.

This type of study gets us much closer.

Second, the dose was not extreme.

Not 10,000 IU. Not megadosing. Just 2,000 IU daily taken consistently.

That stood out because it is also the dose we built D3X around. Not because of this study specifically. D3X existed before these results came out.

We landed on 2,000 IU because it kept showing up in the research as a middle ground that made sense. Enough to matter for many adults. Still within commonly accepted safety guidelines. Realistic for something people could actually take every day.

That does not mean 2,000 IU is perfect for everyone. Individual needs vary. But it was interesting to see a large, long-term study land in the same place.

Third, this lasted four years.

Not four weeks. Not a short intervention.

Four years of doing something simple every day and ending up with a measurable difference.

WHAT IT DOESN'T SAY

This part matters.

The study did not show that vitamin D cures, treats, or prevents any specific disease.

It measured a marker associated with aging, and vitamin D moved that marker in a favorable direction.*

That is interesting.

It is also different from proving clinical outcomes.

One reason researchers care about biological aging in the first place is because aging sits upstream of many of the diseases people worry about. Heart disease, cognitive decline, type 2 diabetes, and many cancers become more common as we age.

That does not mean changing a marker automatically changes disease risk. This study did not show that.

But it helps explain why findings like this get attention. If something affects a process tied to aging, the obvious next question is whether that eventually leads to broader health effects over time.

That question is still open.

WHY THIS LANDS FOR ME

The thing that stuck with me was not the dose.

It was the consistency.

Participants did this every day for four years.

That is where health advice often breaks down. Not because the science is wrong. Because consistency is harder than people think.

D3X started with a simple belief. If consistency matters, products should be built around consistency.

Not just ingredients.

Routine.

Actually making the habit easy enough to stick with.

Because a supplement sitting in a cupboard does nothing.

The science around vitamin D keeps getting more interesting.

The harder question is whether people actually take it every day.

Time to get serious about your D.